Tag: Insmed

Finance

Biotech Decliners: Insmed Incorporated (NASDAQ:INSM), 22nd Century Group Inc (NYSEMKT:XXII), Concert Pharmaceuticals Inc (NYSE:JMPC), Relypsa Inc (NASDAQ:RLYP)

Insmed Incorporated (NASDAQ:INSM) on May 13, 2014 announces that multiple posterpresentations reporting data on ARIKAYCE(TM), or liposomal amakacinfor inhalation, for the treatment of Pseudomonas aeruginosainfections in cystic fibrosis (CF) patients and for the treatment ofpatients with treatment-resistant nontuberculous mycobacterial (NTM)lung infections will be presented at the American Thoracic SocietyAnnual Meeting 2014, taking place May 16-21 in San Diego, California. Insmed Incorporated (NASDAQ:INSM) stock performance was … Continue reading Biotech Decliners: Insmed Incorporated (NASDAQ:INSM), 22nd Century Group Inc (NYSEMKT:XXII), Concert Pharmaceuticals Inc (NYSE:JMPC), Relypsa Inc (NASDAQ:RLYP)

Kevin Long
Finance

Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Earlier this week, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has initiated a phase II pivotal study that will evaluate the safety and efficacy of AP26113 in locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer’s (PFE – Analyst Report) Xalkori (crizotinib). Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) stock performance was -1.16% in last session and finished the … Continue reading Biotech Active Movers: Ariad Pharmaceuticals (NASDAQ:ARIA), Insmed Incorporated (NASDAQ:INSM), Rexahn Pharmaceuticals (NYSEMKT:RNN), Inovio Pharmaceuticals (NYSEMKT:INO)

Jayne Crisman
Finance

Biotech Bearish Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Galena Biopharma (NASDAQ:GALE), Insmed Incorporated (NASDAQ:INSM), CytRx Corporation (NASDAQ:CYTR)

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) was upgraded by investment analysts at Maxim Group from a “hold” rating to a “buy” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm currently has a $6.00 price target on the stock. Maxim Group’s target price would suggest a potential upside of 62.16% from the stock’s previous close. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was -7.30% … Continue reading Biotech Bearish Stocks: Achillion Pharmaceuticals (NASDAQ:ACHN), Galena Biopharma (NASDAQ:GALE), Insmed Incorporated (NASDAQ:INSM), CytRx Corporation (NASDAQ:CYTR)

Kristen Barton